Can Vivus Inc. Ride Qsymia to Market Success and Big Returns?

Since last week's news that Vivus, Inc. (NASDAQ:VVUS) received FDA approval for its obesity drug Qsymia, the raging battle between Vivus and Arena Pharmaceuticals, Inc.

Keep Reading →